Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2013

View Archived Issues

Development of a potassium channel activator for the treatment of migraine

Novel phosphate adsorbers for the treatment of patients with renal failure

miRNA improves survival in a murine model of ALS

Development of two novel murine models of filarial pathology

Biotest and EpiVax to develop non-immunogenic treatment for hemophilia A

Stallergenes and ActoGeniX to develop treatments for allergic diseases

OncoMed and Celgene sign agreement for anti-cancer stem cell product candidates

Anti-infective startup company Auspherix launched

RXi Pharmaceuticals reports additional data from phase I RXI-109 trial

Genentech begins phase II trial of DNIB-0600A

Novel Nampt inhibitors presented by AbbVie

Novel muscarinic M4 positive allosteric modulator for the treatment of Huntington's disease

Incyte Corp. presents new JAK1 inhibitors

Researchers at Actelion Pharmaceuticals synthesize novel LXA4 receptor agonists

Idera Pharmaceuticals opens enrollment in phase I/II trial of IMO-8400

Glenmark Pharmaceuticals discloses novel ROR-gamma modulators

GlaxoSmithKline patents new EZH2 inhibitors for cancer

Bristol-Myers Squibb synthesizes new GPR119 receptor agonists

3-V Biosciences begins phase I TVB-2640 trial

Galapagos reports phase I findings on GLPG-1205

Sanofi launches ComPlavin combination tablets in Japan

Topline data reported from phase II study of ChemoCentryx's CCX-168

FDA grants orphan drug designation to Immunomedics' IMMU-132 for SCLC

The Medicines Company gains anti-infective assets through Rempex acquisition

Puma Biotechnology reports data from I-SPY 2 trial of neratinib

OncoMed studies vantictumab combination therapy for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...